Targeting tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): A promising therapeutic strategy in gliomas

Seminars in Pediatric Neurology

Volumn 22, Issue 1, 2015, Pages 35-39

  Alexiou, George A ^a   Tsamis, Konstantinos I ^a   Kyritsis, Athanasios P ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; DRUG HALF LIFE; GLIOMA; HUMAN; INTRACELLULAR SIGNALING; NECROPTOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; BRAIN NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METABOLISM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOMA; HUMANS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84929292522     PISSN: 10719091     EISSN: 15580776     Source Type: Journal    
DOI: 10.1016/j.spen.2014.12.002     Document Type: Review

References (45)

1. Alexiou G.A., Moschovi M., Stefanaki K., et al. Epidemiology of pediatric brain tumors in Greece (1991-2008). Experience from the Agia Sofia Children[U+05F3]s Hospital. Cent Eur Neurosurg 2011, 72(1):1-4.
2. Patel S., Bhatnagar A., Wear C., et al. Are pediatric brain tumors on the rise in the USA? Significant incidence and survival findings from the SEER database analysis. Childs Nerv Syst 2014, 30:147-154.
3. Ostrom Q.T., Gittleman H., Farah P., et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013, 15:1-56.
4. Schomas D.A., Laack N.N., Rao R.D., et al. Intracranial low-grade gliomas in adults: 30-Year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 2009, 11:437-445.
5. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
6. Verhagen A.M., Ekert P.G., Pakusch M., et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
7. Chang D.W., Xing Z., Capacio V.L., et al. Interdimer processing mechanism of procaspase-8 activation. EMBO J 2003, 22:4132-4142.
8. Pitti R.M., Marsters S.A., Ruppert S., et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690.
9. Emery J.G., McDonnell P., Burke M.B., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273:14363-14367.
10. Kuijlen J.M., Mooij J.J., Platteel I., et al. TRAIL-receptor expression is an independent prognostic factor for survival in patients with a primary glioblastoma multiforme. J Neurooncol 2006, 78:161-171.
11. Tsamis K.I., Alexiou G.A., Vartholomatos E., et al. Combination treatment for glioblastoma cells with tumor necrosis factor-related apoptosis-inducing ligand and oncolytic adenovirus delta-24. Cancer Invest 2013, 31:630-638.
12. Yu X., Deng Q., Bode A.M., et al. The role of necroptosis, an alternative form of cell death, in cancer therapy. Expert Rev Anticancer Ther 2013, 13:883-893.
13. Huang C., Luo Y., Zhao J., et al. Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One 2013, 8:e66326.
14. Jouan-Lanhouet S., Arshad M.I., Piquet-Pellorce C., et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ 2012, 19:2003-2014.
15. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005, 12:228-237.
16. Zhang Y., Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008, 6:1861-1871.
17. Jane E.P., Premkumar D.R., Pollack I.F. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-κB signaling pathway. Mol Cancer Ther 2011, 10:198-208.
18. Kyritsis A.P., Tachmazoglou F., Rao J.S., et al. Bortezomib sensitizes human astrocytoma cells to tumor necrosis factor related apoptosis-inducing ligand induced apoptosis. Clin Cancer Res 2007, 13:6540-6541.
19. Panner A., James C.D., Berger M.S., et al. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 2005, 25:8809-8823.
20. Quintavalle C., Donnarumma E., Iaboni M., et al. Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene 2013, 32:4001-4008.
21. Verbrugge I., de Vries E., Tait S.W., et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 2008, 27:574-584.
22. Kim M.R., Lee J.Y., Park M.T., et al. Ionizing radiation can overcome resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett 2001, 505:179-184.
23. Ding L., Yuan C., Wei F., et al. Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 2011, 29:511-520.
24. Calzolari A., Saulle E., De Angelis M.L., et al. Salinomycin potentiates the cytotoxic effects of TRAIL on glioblastoma cell lines. PLoS One 2014, 9:e94438.
25. Yoon M.J., Kang Y.J., Kim I.Y., et al. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis 2013, 34:1918-1928.
26. Yulyana Y., Endaya B.B., Ng W.H., et al. Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma. Stem Cells Dev 2013, 22:1870-1882.
27. Schultze K., Böck B., Eckert A., et al. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006, 11:1503-1512.
28. Hetschko H., Voss V., Horn S., et al. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 2008, 86:265-272.
29. Cristofanon S., Fulda S. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 2012, 3:e432.
30. Unterkircher T., Cristofanon S., Vellanki S.H., et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011, 17:4019-4030.
31. Fulda S., Wick W., Weller M., et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002, 8:808-815.
32. Puduvalli V.K., Sampath D., Bruner J.M., et al. TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation. Apoptosis 2005, 10:233-243.
33. Alexiou G.A., Voulgaris S. The role of the PTEN gene in malignant gliomas. Neurol Neurochir Pol 2010, 44:80-86.
34. Bagci-Onder T., Wakimoto H., Anderegg M., et al. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 2011, 71:154-163.
35. Kyritsis A.P., Sioka C., Rao J.S. Viruses, gene therapy and stem cells for the treatment of human glioma. Cancer Gene Ther 2009, 16:741-752.
36. Fueyo J., Gomez-Manzano C., Alemany R., et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000, 19:2-12.
37. Mitlianga P.G., Sioka C., Vartholomatos G., et al. p53 enhances the Delta-24 conditionally replicative adenovirus anti-glioma effect. Oncol Rep 2006, 15:149-153.
38. Rozanov D.V., Savinov A.Y., Golubkov V.S., et al. Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther 2009, 8:1515-1525.
39. Yu R., Deedigan L., Albarenque S.M., et al. Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects. Cell Death Dis 2013, 4:e503.
40. Balyasnikova I.V., Prasol M.S., Ferguson S.D., et al. Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. Mol Ther 2014, 22:140-148.
41. Perlstein B., Finniss S.A., Miller C., et al. TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol 2013, 15:29-40.
42. Li X., Mao Q., Wang D., et al. A fiber chimeric CRAd vector Ad5/11-D24 double-armed with TRAIL and arresten for enhanced glioblastoma therapy. Hum Gene Ther 2012, 23:589-596.
43. Herbst R.S., Eckhardt S.G., Kurzrock R., et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010, 28:2839-2846.
44. Graves J.D., Kordich J.J., Huang T.H., et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 2014, 26:177-189.
45. Lemke J., von Karstedt S., Zinngrebe J., et al. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014, 21:1350-1364.